Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate [Seeking Alpha]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Seeking Alpha
Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancing Regeneron's oncology presence. Regeneron benefits financially from Dupixent sales and a strong balance sheet, indicating robust financial health and investment in pipeline development. I recommend buying Regeneron shares, due to diversified product strength, pipeline potential, and manageable risks despite market challenges. Regeneron: Sailing the Eye of the Market Storm with Eylea HD I last covered Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) in August, right after it received FDA approval for its high-dose Eylea (Eylea HD), a blockbuster drug for the treatment of wet age-related macular degeneration [AMD]. My recommendation was "buy," and the stock, up 16% since that call, is essentially even with the broader market. For some more background: Eylea is one of a few vascular endothelial growth factor (VEGF) inhibitors utilized for wet AMD. These therapies are typically utilized fi
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Medigene AG reports Financial Results and Business Update for Q1 2024 [Yahoo! Finance]Yahoo! Finance
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Regeneron (REGN) Reports Next Week: What You Should Expect [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study [Yahoo! Finance]Yahoo! Finance
- AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study [Reuters]Reuters
REGN
Earnings
- 2/2/24 - Beat
REGN
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- REGN's page on the SEC website